Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...
Menarini Asia-Pacific today announced an exclusive partnership with Pharmacosmos A/S to register, commercialise and ...
Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, ...
Anktiva shows strong NMIBC results and pipeline upside, but valuation, dilution and cash burn raise risk—read now.
Continued low early termination rate (4.5%) among the first 200 patients enrolled in the study suggests Halneuron® and placebo treatment have been well tolerated - ...
Bangladesh’s pharmaceutical industry’s next phase of growth will depend on sustained investment in research and development, ...
Merck & Co.’s almighty Keytruda has become the first PD-1 inhibitor to show a benefit as a single agent for the front-line treatment of a subtype of endometrial cancer. | Merck & Co.’s almighty ...
A new treatment for patients with uveal melanoma is now available in Virginia for the first time through UVA Health, offering ...
Mohawk Valley Health System (MVHS) announced that it will now offer cooling caps to reduce hair loss for cancer patients ...
The firm said the AZUR-1 trial, evaluating Jemperli in patients with dMMR and MSI-high tumors met its primary endpoint.
GSK's pivotal AZUR-1 trial of cancer immunotherapy Jemperli, as a way to delay or eliminate surgery in pre-operative rectal ...
The US Food and Drug Administration (FDA) has approved two of Merck & Co's (MSD) Keytruda (pembrolizumab) and Keytruda Qlex ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results